SOUTH SAN FRANCISCO, Calif., July 29, 2024 (GLOBE NEWSWIRE) -- Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize ...
The decision to discontinue the program was based on data indicating “insufficient efficacy in the target population.” Johnson & Johnson is ending the phase 3 VENTURA clinical development program ...
TORONTO--(BUSINESS WIRE)--Cybin Inc. (NYSE American:CYBN) (Cboe CA:CYBN) (“Cybin” or the “Company”), a clinical-stage breakthrough neuropsychiatry company committed to revolutionizing mental ...
Huntsman Cancer Institute at the University of Utah stands at the forefront of innovative cancer research and treatment. Phase 1 clinical trials are key to finding better ways to treat cancer safely ...
– Phase III GRADUATE studies did not meet their primary endpoints of slowing clinical decline in people with early Alzheimer’s – SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of ...
Developing behavioral intervention to support molecular testing of patients with biliary tract cancer. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...
The Office for Research has also developed the Program Evaluation Core (“PEC”) to address the program evaluation needs of training grants. The PEC provides a range of pre- and post-award services ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results